Tetra Bio-Pharma

114 articles with Tetra Bio-Pharma

• Tetra Bio-Pharma Announces Positive Initial Clinical Data from Both of its Ongoing Phase 2 Clinical Trials of QIXLEEF

  11/29/2021

  Tetra Bio-Pharma Inc. today announced positive initial clinical data from its ongoing Phase 2 clinical trials (REBORN © 1 and PLENITUDE © ) of QIXLEEF™   for cancer pain.  

• 

  Promising Signals Emerge from Two Phase II Cancer Studies

  11/29/2021

  Two biopharma companies developing therapeutics in the oncology space begin the week with strong signals in Phase II.  

• Tetra Bio-Pharma Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines Agency

  10/21/2021

  Tetra Bio-Pharma Inc. announced that the European Medicines Agency Committee for Orphan Medicinal Products issued a positive opinion on the Company's application for Orphan Drug Designation for its investigational medicine QIXLEEF™ as a potential treatment for Complex Regional Pain Syndrome, a chronic neuropathic pain condition.

• Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™

  10/14/2021

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development provided an update on the progress and significant achievements of its lead investigational drug, QIXLEEF™.

• REDUVO - A Major Milestone for Tetra Bio-Pharma Inc.

  10/5/2021

  Tetra is gearing up to launch REDUVO™, its first cannabinoid-derived medicine, in Canada . REDUVO™ 5-year cumulative gross sales expected to reach $121M .

• Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™

  9/2/2021

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development is pleased to announce that it received the Scientific Advice Assessment Report from the Malta Medicines Authority.

• Tetra Bio-Pharma Accelerates REBORN1 Trial

  7/12/2021

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that the Central Ethics Committee has approved the proposed protocol modifications allowing additional immediate release oral opioids to be used as comparators in the REBORN1© study.

• Significant Discovery Reveals New Antiviral Properties of Tetra Bio-Pharma's Innovative Drug ARDS-003

  6/21/2021

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development announced that its investigational new drug ARDS-003 has been studied in a viral infected organoid model as part of a research collaboration between Targeted Pharmaceuticals and George Mason University.

• Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting

  6/2/2021

  Tetra Bio-Pharma Inc. announced today that Health Canada has accepted its New Drug Submission (NDS) for REDUVO™ and has formally entered the final review phase in the drug review process.

• Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain

  5/11/2021

  First ever clinical trial using pharmaceutical grade cannabis medication for use in managing uncontrolled cancer pain due to advanced cancer

• Tetra Bio-Pharma Announces Start of the REBORN1(C) Clinical Trial

  5/6/2021

  First ever Phase 2 clinical trial designed to evaluate the effect of cannabis against an opioid treatment QIXLEEF has the potential to transform the pain market

• Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios

  5/5/2021

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development announced the signing of a Definitive Agreement with DanCann Pharma A/S for the exclusive distribution of Reduvo™ Adversa®, QIXLEEF™ and ENJOUCA™ in Denmark, Norway, Sweden, Finland, and Germany.

• Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals

  5/4/2021

  Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1) , a biopharmaceutical pioneer in immunomodulator drug discovery and development is pleased to announce that it has received authorization from the Veterinary Drugs Directorate of Health Canada for a one year extension to continue the clinical trial

• Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada

  5/3/2021

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development announced that the Company has been granted a Health Canada Drug Establishment License to distribute REDUVO soft gel capsules in Canada.

• Tetra Bio-Pharma Submits Request for Scientific Advice to Malta Medicines Authority

  4/28/2021

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development announced that it has submitted a request to the Malta Medicines Authority for a Scientific Opinion on its investigational new drug QIXLEEF for Tetra's clinical trial programs.

• Tetra Bio-Pharma Provides an Update on its U.S. REBORN1 Clinical Trial

  4/23/2021

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in cannabinoid-derived drug discovery and development is pleased to announce that it has shipped the investigational new drug, QIXLEEF, to the USA for the initiation of the REBORN1 study

• Tetra Bio-Pharma Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis

  4/15/2021

  Tetra Bio-Pharma Inc., a biopharmaceutical pioneer in immunomodulator drug discovery and development announces the granting of a new patent from the United States Patent and Trademark Office for patent application number 16/190,450.

• Tetra Bio-Pharma Provides Update on Its New Drug Submission Application in Canada

  4/14/2021

  Tetra Bio-Pharma Inc., a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have advanced the REDUVO soft gel capsules New Drug Submission file by responding to a request for more information from Health Canada, as previously announced on March 15, 2021.

• FDA Provides Positive Feedback on Tetra Bio-Pharma's Application for ARDS-003 Clinical Development in COVID-19 Patients

  4/5/2021

  FDA acknowledged that the preclinical safety data are acceptable to file an Investigational New Drug Application (IND) aimed at treating hospitalized COVID-19 patients at risk of developing ARDS

• Tetra Bio-Pharma Receives Second Compliant Rating on Inspection from Health Canada

  4/1/2021

  Tetra Bio-Pharma Inc., a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have received a notice of compliance for its Drug Establishment License following an audit by the Drug GMP Inspection Program of Health Canada.